0001562180-19-004217.txt : 20190808
0001562180-19-004217.hdr.sgml : 20190808
20190808164010
ACCESSION NUMBER: 0001562180-19-004217
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190806
FILED AS OF DATE: 20190808
DATE AS OF CHANGE: 20190808
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lizzul Paul F.
CENTRAL INDEX KEY: 0001711462
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38155
FILM NUMBER: 191010145
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD
STREET 2: SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sienna Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001656328
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273364627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
BUSINESS PHONE: (818) 629-2256
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
FORMER COMPANY:
FORMER CONFORMED NAME: Sienna Labs, Inc.
DATE OF NAME CHANGE: 20151020
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-08-06
false
0001656328
Sienna Biopharmaceuticals, Inc.
SNNA
0001711462
Lizzul Paul F.
C/O SIENNA BIOPHARMACEUTICALS, INC.
30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE
CA
91362
false
true
false
false
Chief Medical Officer
Common Stock
2019-08-06
4
A
false
55000.00
A
196488.00
D
Common Stock
10557.00
I
See Footnote
Stock Options (Right to buy)
15.08
2019-08-06
4
D
false
48720.00
D
2028-06-01
Common Stock
48720.00
0.00
D
Stock Options (Right to buy)
15.00
2019-08-06
4
D
false
11926.00
D
2027-07-26
Common Stock
11926.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
14904.00
D
2019-01-01
2029-01-01
Common Stock
14904.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
22500.00
D
2029-01-01
Common Stock
22500.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
22500.00
D
2029-01-01
Common Stock
22500.00
0.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
11926.00
A
2027-07-26
Common Stock
11926.00
11926.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
48720.00
A
2028-06-01
Common Stock
48720.00
48720.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
14904.00
A
2019-01-01
2029-01-01
Common Stock
14904.00
14904.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
22500.00
A
2029-01-01
Common Stock
22500.00
22500.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
22500.00
A
2029-01-01
Common Stock
22500.00
22500.00
D
Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
The shares are directly held by Lizzul Living Trust.
The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Timothy K. Andrews, attorney-in-fact for Paul F. Lizzul
2019-08-08